Results 31 to 40 of about 5,781 (240)

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

EJNMMI Research, 2022
Background Receptor saturation during peptide receptor radionuclide therapy (PRRT) could result in altered [177Lu]Lu-HA-DOTATATE uptake in tumors and organs.
Hinke Siebinga, Chayenne H. A. M. Veerman, Linda de Wit-van der Veen, Marcel P. M. Stokkel, Jeroen J. M. A. Hendrikx, Else A. Aalbersberg   +5 more
doaj   +1 more source

Challenges in Von Hippel–Lindau’s disease: PRRT in patients on hemodialysis

Endocrinology, Diabetes & Metabolism Case Reports, 2022
Von Hippel–Lindau’s disease (VHL) is a hereditary tumor syndrome characterized by its prototype lesions, hemangioblastomas, and renal cell carcinomas. Treatment for renal cell carcinomas can ultimately result in long-term dialysis.
N Ayub, A J A T Braat, H J L M Timmers, M G E H Lam, R S van Leeuwaarde   +4 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation [PDF]

Breast Care, 2012
Breast cancer (BC) is the most frequent cancer in European women with nearly 30% of the patients eventually developing metastases. Neuroendocrine differentiation is a rare event, but overexpression of somatostatin receptors in BC has been reported in many studies.A patient with liver metastases from BC was treated with peptide receptor radionuclide ...
Giordano Savelli, Alberto Zaniboni, Francesco Bertagna, Giovanni Bosio, Lutfun Nisa, Carlo Rodella, Giorgio Biasiotto, Giovanni Bettinsoli, Elena Migliorati, Alessia Peli, Roberta Falchi, Francesca Giuffrida, Raffaele Giubbini   +12 more
openalex   +3 more sources

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +1 more source

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review

EJNMMI Research, 2018
Background The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation.
Daphne Merel Valerie Huizing, Berlinda Jantina de Wit-van der Veen, Marcel Verheij, Marcellus Petrus Maria Stokkel   +3 more
doaj   +1 more source

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group [PDF]

, 2019
Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established.
Badalamenti, G., Bianco, A., Colao, A., De Divitiis, C., Di Maio, S., Di Sarno, A., Dolce, P., Faggiano, A., Guarnotta, V., Leo, S., Mocerino, C., Modica, R., Ottaviano, M., Palmieri, G., Puliafito, I., Riccardi, F., Tafuto, S., Tozzi, L.   +17 more
core   +1 more source

Peptide receptor radionuclide therapy [PDF]

, 2005
Peptide receptor radionuclide therapy is a new treatment modality for patients with inoperable or metastasised neuroendocrine gastroenteropancreatic tumours.
Esser, J.-P. (Jan-Paul), Jong, M. (Marcel) de, Krenning, E.P. (Eric), Kwekkeboom, D.J. (Dirk Jan), Teunissen, J.J.M. (Jaap), Valkema, R. (Roelf)   +5 more
core   +1 more source

Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Pharmaceuticals, 2019
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.
Ute Hennrich, Klaus Kopka
doaj   +1 more source

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Cancer Medicine, 2021
Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors.
Marianne S. Elston, Amanda Love, Dev Kevat, Richard Carroll, Zhen Rong Siow, Sharon Pattison, Veronica Boyle, Eva Segelov, Andrew H. Strickland, David Wyld, Richard Gauci, Kim Kennedy, David Ransom, the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)   +13 more
doaj   +1 more source

Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib [PDF]

, 2016
Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled peptides (peptide receptor radionuclide therapy or PRRT).
Beerens, C.E.M.T. (Cecile), Doukas, M. (Michael), Eijck, C.H.J. (Casper) van, Gent, D.C. (Dik) van, Jong, M. (Marcel) de, Nonnekens, J. (Julie), Suker, M. (Mustafa), van Kranenburg, M. (Melissa)   +7 more
core   +1 more source